Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma
- 29 June 2022
- journal article
- research article
- Published by Elsevier in Auris Nasus Larynx
- Vol. 50 (4) , 641-645
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (18K09339)
This publication has 10 references indexed in Scilit:
- A Case Treated With Photoimmunotherapy Under a Navigation System for Recurrent Lesions of the Lateral Pterygoid MuscleIn Vivo, 2022
- Photoimmunotherapy for Managing Recurrent Laryngeal Cancer Cervical Lesions: A Case ReportCase Reports in Oncology, 2022
- Phase 1/2a, open‐label, multicenter study of RM‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinomaHead & Neck, 2021
- A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinomaInternational Journal of Clinical Oncology, 2021
- Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neckInternational Journal of Clinical Oncology, 2021
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunityOncotarget, 2017
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane moleculesNature Medicine, 2011
- Epidermal Growth Factor Receptor Biology in Head and Neck CancerJournal of Clinical Oncology, 2006